Dr. Sankhala on the TRC105/Pazopanib Combination in Angiosarcoma

Video

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

Pazopanib is approved for the treatment of advanced angiosarcoma, but evidence of activity has been modest, with a median progression-free survival (PFS) of 3 months, and a median overall survival (OS) of 9.9 months, according to a recent study in which none of the patients achieved complete responses.

Endoglin is a surface receptor expressed on activated endothelium, including tumor vasculature, and it is also expressed on angiosarcoma tumor tissue and could be a potential driver of this endothelial malignancy. The receptor may mediate resistance to pazopanib. A phase Ib/IIa study of the endoglin antibody TRC105 combined with pazopanib in patients with advanced soft tissue sarcoma was previously reported at the 2016 ASCO meeting. The current results demonstrate this combination’s activity in an expansion cohort of patients with angiosarcoma.

In this expansion cohort, the combination treatment was both active and well tolerated, and it led to durable complete responses. A global phase III study of pazopanib with or without TRC105 is now planned.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute